Mirai Bio, an innovation partner for the co-creation of fully optimized genetic medicines, has appointed Jens Vogel, Ph.D. as the company’s President and Chief Operating Officer.
 
Dr. Vogel will guide the Company’s growth and platform development as it expands partnerships with companies across the biotech industry who are seeking to develop novel genetic medicines.

Experience 

Vogel joins Mirai from Bayer Pharmaceuticals where he was Global Head of Biotech, responsible for supporting the company’s $4 billion commercial biologics portfolio and development of its multimodality pipeline through operations at multiple sites around the world.
 
Before Bayer, he was President and CEO of Boehringer Ingelheim Fremont Inc., where he built the company’s end-to-end development and manufacturing capabilities for internal products and customers. Under his leadership, his teams filed over 70 Investigational New Drug applications (INDs), helped bring ten biologics to market, and created innovative industrialization platforms for new modalities, such as cell and gene therapies.
 
Hari Pujar, Ph.D., an Operating Partner at Flagship Pioneering and Mirai’s co-founder and Founding President, remarked, “In three years, Mirai has gone from an idea to a true platform that has unlocked delivery of nucleic acids to multiple cell and tissue types for the benefit of our partners. We expect that progress to only accelerate under Jens’ leadership.”
 
Vogel added, “With the tremendous innovation today across the industry in nucleic acid-based therapies, we are shifting from making hardware to a software model by reprogramming cells in vivo to correct disease. Realizing the full potential of this remarkable transition requires solving for in vivo delivery and doing so – for the benefit of the entire industry – will open the doors to enormous value for patients. By combining innovations across design, delivery, and manufacturing in one open platform, Mirai is already out in front in this mission, and I look forward to guiding the next big leaps forward in the growth of our platform, partnerships, and company.”